^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Adrenergic uptake inhibitor

    Related drugs:
    17d
    AnTi-FREEZE: Pharmacologically Modulating the Noradrenergic Arousal System to Reduce Freezing of Gait in Parkinson's Disease: a Multi-centre and Multi-modal Approach (clinicaltrials.gov)
    P3, N=60, Not yet recruiting, Radboud University Medical Center
    New P3 trial
    22d
    Repositioning serotonergic antagonists as therapeutic agents in gastric cancer: induction of apoptosis, inhibition of cell migration, and cell cycle arrest in AGS cells. (PubMed, Cytotechnology)
    Imipramine induced G1/S phase arrest, whereas tropisetron, ketanserin, and cyproheptadine increased the sub-G1 cell population. Gene expression analysis revealed decreased Bcl-2 and PCNA levels and increased Bax expression.These findings suggest the potential of tropisetron, imipramine, ketanserin, and cyproheptadine as repurposed therapeutic agents for gastric cancer.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • PCNA (Proliferating cell nuclear antigen) • SLC6A4 (Solute Carrier Family 6 Member 4)
    |
    imipramine
    1m
    The Effect of Topical Imipramine on Photodynamic Therapy-Mediated Immunosuppression on Forearms or Face on US Veterans (clinicaltrials.gov)
    P2, N=48, Recruiting, VA Office of Research and Development | N=24 --> 48
    Enrollment change
    |
    imipramine
    2ms
    Pharmacological Treatment Targeting Endotypic Traits of Obstructive Sleep Apnea (clinicaltrials.gov)
    P4, N=45, Completed, China Medical University Hospital | Recruiting --> Completed | N=132 --> 45
    Trial completion • Enrollment change
    2ms
    Characterization and Prognostic Impact of Fascin Expression in the Tumor Microenvironment of Triple-Negative Breast Cancer: Clues for a Tailored Therapy. (PubMed, Lab Invest)
    These findings highlight the dual role of fascin in tumor cells and the tumor microenvironment (TME), and reinforce its potential as a biomarker for personalized TNBC therapies. Ongoing clinical trials, including HITCLIF, are exploring the efficacy of imipramine in patients with fascin-overexpressing cancers, paving the way for targeted treatment strategies.
    Journal • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • BCL2 (B-cell CLL/lymphoma 2) • FSCN1 (Fascin Actin-Bundling Protein 1)
    |
    HER-2 expression
    |
    imipramine
    2ms
    Progressive Relaxation and Psychoeducation in Patients With Hematological Malignancies (clinicaltrials.gov)
    P=N/A, N=75, Not yet recruiting, Necmettin Erbakan University
    New trial
    2ms
    Role of the Noradrenergic System in the Regulation of Learning Dynamics: Evaluation of the Effect of a Low-dose Selective Noradrenaline Reuptake Inhibitor (NOISYXETINE) (clinicaltrials.gov)
    P=N/A, N=160, Recruiting, Centre Hospitalier St Anne
    New trial
    3ms
    Sorafenib generates microvesicle particles in non-small cell lung cancer. (PubMed, Tumor Discov)
    Moreover, co-treatment with imipramine enhanced the cytotoxic effects of sorafenib, suggesting that targeting MVP-associated pathways may improve sorafenib response. Collectively, these findings offer mechanistic insight into how sorafenib modulates MVP release and supports the therapeutic potential of combining tyrosine kinase inhibitors with agents that disrupt MVP biogenesis in NSCLC.
    Journal
    |
    MVP (Major Vault Protein)
    |
    sorafenib • imipramine
    5ms
    Imipramine Inhibits Osteosarcoma Invasion via Src Inactivation and Caspase-Dependent Apoptosis. (PubMed, J Cell Mol Med)
    Imipramine exerts potent anti-OS effects by suppressing Src-mediated invasion and enhancing caspase-dependent apoptosis through extrinsic and intrinsic pathways. It inhibits tumour progression without inducing systemic toxicity, demonstrating its potential as a therapeutic candidate for OS.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1) • CASP3 (Caspase 3) • CASP8 (Caspase 8) • CASP9 (Caspase 9) • XIAP (X-Linked Inhibitor Of Apoptosis) • SNAI2 (Snail Family Transcriptional Repressor 2)
    |
    imipramine
    5ms
    Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma (clinicaltrials.gov)
    P2, N=25, Recruiting, The University of Texas Health Science Center at San Antonio | Trial primary completion date: Feb 2026 --> Aug 2026
    Trial primary completion date
    |
    lomustine • imipramine
    6ms
    Transcranial Direct Current Stimulation Combined with Atomoxetine Hydrochloride in the Comprehensive Treatment of Attention Deficit Hyperactivity Disorder: A Clinical Study (ChiCTR2500104085)
    P=N/A, N=80, Recruiting, Children's Hospital Affiliated to Chongqing Medical University; Children's Hospital Affiliated to Chongqing Medical University
    New trial
    7ms
    Use of Accelerometer for Quantification of Neurogenic Orthostatic Hypotension Symptoms (clinicaltrials.gov)
    P=N/A, N=29, Recruiting, Vanderbilt University Medical Center | Trial completion date: Oct 2025 --> Oct 2027 | Trial primary completion date: Jun 2025 --> Jun 2027
    Trial completion date • Trial primary completion date